Stay updated on Mirvetuximab vs Bevacizumab in Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Mirvetuximab vs Bevacizumab in Ovarian Cancer Clinical Trial page.

Latest updates to the Mirvetuximab vs Bevacizumab in Ovarian Cancer Clinical Trial page
- Check3 days agoChange DetectedAdded Revision: v3.5.2 and removed Revision: v3.5.0.SummaryDifference0.0%

- Check10 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check32 days agoChange DetectedThe page revision changed from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check46 days agoChange DetectedSite revision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check54 days agoChange DetectedUpdated the study site list with many new locations and institutions, and removed several previously listed sites. The total number of locations is now 264.SummaryDifference3%

- Check68 days agoChange DetectedFallopian tube cancer was added to the Conditions list and a Genetic and Rare Diseases Information Center resource was linked in Resources. The page revision is updated to v3.4.2 from v3.4.1.SummaryDifference0.1%

- Check75 days agoChange DetectedRevision: v3.4.1 was added and Revision: v3.4.0 was removed, which are minor UI/version changes not affecting study content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Mirvetuximab vs Bevacizumab in Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Mirvetuximab vs Bevacizumab in Ovarian Cancer Clinical Trial page.